Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

This observational study is using a type of full-body imaging scan (18FDG PET-CT, which shows where the body is using the most glucose — a sign of cancer activity) to evaluate whether it can predict early on how well immunotherapy — with or without chemotherapy — is working in patients with advanced or metastatic non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced or metastatic non-small cell lung cancer confirmed by pathology - Your doctor has recommended immunotherapy (such as pembrolizumab, nivolumab, or similar drugs), alone or with chemotherapy, as part of your standard care - You have social security coverage **You may NOT be eligible if...** - You are under 18 - You have conditions that prevent you from safely undergoing PET-CT scans - You do not consent to your data being used for research Talk to your doctor to see if this trial is right for you.